A Phase 3, Multicentre, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy and Safety of Daily Oral Administration of BG2109 Alone and in Combination With Add-back Therapy for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women.
Overview
- Phase
- Phase 3
- Intervention
- Add-back therapy
- Conditions
- Uterine Fibroids
- Sponsor
- Bio Genuine (Shanghai) Biotech Co., Ltd.
- Enrollment
- 312
- Locations
- 29
- Primary Endpoint
- Percentage of Responders based on menstrual blood loss (MBL) volume reduction at Week 24.
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
The primary objective of this study is to demonstrate the superior efficacy versus placebo of BG2109 alone and in combination with add-back therapy for the reduction of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.
Detailed Description
The study is a prospective, randomized, parallel group, double-blind, placebo-controlled phase 3 study investigating the efficacy and safety of BG2109 alone and in combination with add-back therapy (Estradiol 1 mg / Norethindrone Acetate 0.5 mg) for the treatment of uterine fibroids in China.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subject is an 18 years and older premenopausal woman.
- •Subject's Body Mass Index ≥ 18 kg/m
- •Subject has a diagnosis of uterine fibroids documented by a pelvic ultrasound.
- •Subject's menstrual cycles is between 21 days and 35 days in the last 3 months.
- •Subject has clinical manifestations of heavy menstrual bleeding.
- •Subject's menstrual blood loss \>80mL for at least 2 menstrual periods assessed at screening using the alkaline hematin method.
Exclusion Criteria
- •The subject is pregnant or breast-feeding or is planning a pregnancy within the duration of the treatment period of the study.
- •The subject has a history of uterus surgery that would interfere with the study.
- •The subject's condition is so severe that she will require surgery within 6 months.
- •The subject have had or are currently suffering from any estrogen- dependent malignancy.
- •The subject has a significant risk of osteoporosis, or have a known history of osteoporosis or other metabolic bone disease.
Arms & Interventions
BG2109 200mg+ABT group
Two tablets of BG2109 100mg + one tablet of add-back therapy, oral, once-daily.
Intervention: Add-back therapy
BG2109 100mg group
One tablet of BG2109 100mg + one tablet of placebo for BG2109 + one tablet of placebo for add-back therapy, oral, once-daily.
Intervention: BG2109
BG2109 100mg group
One tablet of BG2109 100mg + one tablet of placebo for BG2109 + one tablet of placebo for add-back therapy, oral, once-daily.
Intervention: Placebo for BG2109
BG2109 100mg group
One tablet of BG2109 100mg + one tablet of placebo for BG2109 + one tablet of placebo for add-back therapy, oral, once-daily.
Intervention: Placebo for add-back therapy
BG2109 200mg+ABT group
Two tablets of BG2109 100mg + one tablet of add-back therapy, oral, once-daily.
Intervention: BG2109
Placebo group
Two tablets of placebo for BG2109 + one tablet of placebo for add-back therapy, oral, once-daily.
Intervention: Placebo for BG2109
Placebo group
Two tablets of placebo for BG2109 + one tablet of placebo for add-back therapy, oral, once-daily.
Intervention: Placebo for add-back therapy
Outcomes
Primary Outcomes
Percentage of Responders based on menstrual blood loss (MBL) volume reduction at Week 24.
Time Frame: The last 28 days before the Week 24.
MBL will be determined using the Alkaline Hematin method (AHM). Responder means whose MBL less than 80mL during the last 28 days before the Week 24 and more than 50% reduction in MBL compared to the baseline.
Secondary Outcomes
- Time to reduced MBL before the Week 24.(From baseline to Week 24.)
- Percentage of amenorrhea at the Week 24.(From baseline to Week 24.)
- Time to amenorrhea before the Week 24.(From baseline to Week 24.)
- Days of menstrual bleeding in the last 28 days before the Week 24.(The last 28 days before the Week 24.)
- Hemoglobin levels at the Week 24 in the subgroup of subjects with anemia.(The Week 24.)